Study identifier:BY217/M2-112
ClinicalTrials.gov identifier:NCT00430729
EudraCT identifier:N/A
CTIS identifier:N/A
Effect of roflumilast on exacerbation rate in patients with chronic obstructive pulmonary disease. A 52 weeks double blind study with 500mcg roflumilast once daily versus placebo. Ratio-Study.
Chronic Obstructive Pulmonary Disease
Phase 3
No
Roflumilast
All
1100
Interventional
40 Years +
Allocation: Randomized
Endpoint Classification: None
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Sept 2016 by AstraZeneca
AstraZeneca
-
The purpose of this study is to investigate the effect of 500mcg roflumilast vs placebo on exacerbation rate and pulmonary function as well as quality of life in patients with chronic obstructive pulmonary disease (COPD).
Location
Location
Cities in Australia, Australia
Location
Cities in Austria, Austria
Location
Cities in Canada, Canada
Location
Cities in France, France
Location
Cities in Hungary, Hungary
Location
Cities in Italy, Italy
Location
Cities in the Netherlands, Netherlands
Location
Cities in Poland, Poland
Arms | Assigned Interventions |
---|
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.